Roulois David, Loo Yau Helen, Singhania Rajat, Wang Yadong, Danesh Arnavaz, Shen Shu Yi, Han Han, Liang Gangning, Jones Peter A, Pugh Trevor J, O'Brien Catherine, De Carvalho Daniel D
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9, Canada.
Cell. 2015 Aug 27;162(5):961-73. doi: 10.1016/j.cell.2015.07.056.
DNA-demethylating agents have shown clinical anti-tumor efficacy via an unknown mechanism of action. Using a combination of experimental and bioinformatics analyses in colorectal cancer cells, we demonstrate that low-dose 5-AZA-CdR targets colorectal cancer-initiating cells (CICs) by inducing viral mimicry. This is associated with induction of dsRNAs derived at least in part from endogenous retroviral elements, activation of the MDA5/MAVS RNA recognition pathway, and downstream activation of IRF7. Indeed, disruption of virus recognition pathways, by individually knocking down MDA5, MAVS, or IRF7, inhibits the ability of 5-AZA-CdR to target colorectal CICs and significantly decreases 5-AZA-CdR long-term growth effects. Moreover, transfection of dsRNA into CICs can mimic the effects of 5-AZA-CdR. Together, our results represent a major shift in understanding the anti-tumor mechanisms of DNA-demethylating agents and highlight the MDA5/MAVS/IRF7 pathway as a potentially druggable target against CICs.
DNA去甲基化剂已通过未知的作用机制展现出临床抗肿瘤疗效。通过在结肠癌细胞中结合实验分析与生物信息学分析,我们证明低剂量5-氮杂胞苷脱氧核苷(5-AZA-CdR)通过诱导病毒模拟来靶向结肠直肠癌起始细胞(CIC)。这与至少部分源自内源性逆转录病毒元件的双链RNA(dsRNA)的诱导、黑色素瘤分化相关基因5(MDA5)/线粒体抗病毒信号蛋白(MAVS)RNA识别途径的激活以及干扰素调节因子7(IRF7)的下游激活有关。事实上,通过分别敲低MDA5、MAVS或IRF7来破坏病毒识别途径,会抑制5-AZA-CdR靶向结肠直肠癌CIC的能力,并显著降低5-AZA-CdR的长期生长效应。此外,将dsRNA转染到CIC中可模拟5-AZA-CdR的作用。总之,我们的研究结果代表了在理解DNA去甲基化剂抗肿瘤机制方面的重大转变,并突出了MDA5/MAVS/IRF7途径作为针对CIC的潜在可药物靶向。